Jacobs Levy Equity Management
ANTX icon

Jacobs Levy Equity Management’s AN2 Therapeutics ANTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79,359
Closed -$84.9K – 934
2024
Q3 		$84.9K Buy
+79,359
New +$138K ﹤0.01% 936

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Jacobs Levy Equity Management's ANTX Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of AN2 Therapeutics (ANTX) in Q4 2024, closing a stake of 79,359 shares — an estimated $84.9K sold.

Jacobs Levy Equity Management first reported a position in ANTX in Q3 2024 and held it in 1 quarter. The position peaked at $84.9K in Q3 2024. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining AN2 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 79,359 AN2 Therapeutics shares in Q4 2024, an estimated $84.9K.
  • Jacobs Levy Equity Management first reported a position in AN2 Therapeutics in Q3 2024 and held it in 1 quarter.
  • Jacobs Levy Equity Management's AN2 Therapeutics position peaked at $84.9K in Q3 2024.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.